Jiang S, Wang S, Wang Q, et al. - In advanced lung adenocarcinoma patients, researchers determined whether systemic inflammation response index (SIRI) has prognostic value. This study was a retrospective analysis of 245 patients with EGFR-mutant advanced lung adenocarcinoma who were treated with gefitinib, erlotinib, or icotinib. They defined SIRI as neutrophil count×monocyte/lymphocyte count. High SIRI was correlated with male patient, smoker, worse ECOG PS, and 19-DEL mutation. In Kaplan–Meier survival analysis, a significant correlation of ECOG PS, brain metastasis, and SIRI with progression-free survival (PFS) was evident. A significant correlation with overall survival (OS) was demonstrated by gender, ECOG PS, brain metastasis, NLR and SIRI. In multivariate analysis, PFS and OS were independently predicted by SIRI and ECOG PS. Based on these findings, experts inferred that SIRI represents not only an effective but also a convenient marker to predict prognosis in cases with advanced EGFR-mutant lung adenocarcinoma managed with first-generation TKI.